Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo

Implementation of pharmacovigilance (PV) systems in resource-limited countries is a real endeavor. Despite country- and continent-specific challenges, the Democratic Republic of the Congo (DRC) has been able to develop one of the most active PV systems in the sub-Saharan Africa. The World Health Org...

Full description

Bibliographic Details
Main Authors: Didier Nzolo, Andrea Kuemmerle, Yves Lula, Nsengi Ntamabyaliro, Aline Engo, Bibiche Mvete, Jerry Liwono, Mariano Lusakibanza, Gauthier Mesia, Christian Burri, Samuel Mampunza, Gaston Tona
Format: Article
Language:English
Published: SAGE Publishing 2019-07-01
Series:Therapeutic Advances in Drug Safety
Online Access:https://doi.org/10.1177/2042098619864853
id doaj-604029eb03fa41a5b6b5e31fe08c2936
record_format Article
spelling doaj-604029eb03fa41a5b6b5e31fe08c29362020-11-25T03:16:51ZengSAGE PublishingTherapeutic Advances in Drug Safety2042-09942019-07-011010.1177/2042098619864853Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of CongoDidier NzoloAndrea KuemmerleYves LulaNsengi NtamabyaliroAline EngoBibiche MveteJerry LiwonoMariano LusakibanzaGauthier MesiaChristian BurriSamuel MampunzaGaston TonaImplementation of pharmacovigilance (PV) systems in resource-limited countries is a real endeavor. Despite country- and continent-specific challenges, the Democratic Republic of the Congo (DRC) has been able to develop one of the most active PV systems in the sub-Saharan Africa. The World Health Organization (WHO) regional Office identified the DRC experience to set up a PV system for antimalarial drugs safety monitoring as a ‘best practice’ that needed to be documented in order to help DRC improve its PV system and to be scaled up in other African countries. In response to the WHO request, a best practices and bottlenecks analysis was conducted in 2015. This analysis was updated in 2018 in the light of the minimum requirements of the WHO to set up a PV system taking into account other guidance for PV systems. The following themes were retained for analysis: (1) creation of the national PV center; (2) implementation of PV in the health system; (3) data collection and analysis; (4) collaboration with public health programs; (5) collaboration with the National Regulatory Authority. Lessons learnt from the DRC experience show that it is possible to implement PV systems in order to promote patients’ safety in resource limited sub-Saharan African countries with no guaranteed funding. The ability of national PV centers to collaborate with Public health stakeholders, including public health authorities at all levels as well as public health programs, and to use existing health information systems are considered the main key to success and may substantially reduce the cost of PV activities.https://doi.org/10.1177/2042098619864853
collection DOAJ
language English
format Article
sources DOAJ
author Didier Nzolo
Andrea Kuemmerle
Yves Lula
Nsengi Ntamabyaliro
Aline Engo
Bibiche Mvete
Jerry Liwono
Mariano Lusakibanza
Gauthier Mesia
Christian Burri
Samuel Mampunza
Gaston Tona
spellingShingle Didier Nzolo
Andrea Kuemmerle
Yves Lula
Nsengi Ntamabyaliro
Aline Engo
Bibiche Mvete
Jerry Liwono
Mariano Lusakibanza
Gauthier Mesia
Christian Burri
Samuel Mampunza
Gaston Tona
Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo
Therapeutic Advances in Drug Safety
author_facet Didier Nzolo
Andrea Kuemmerle
Yves Lula
Nsengi Ntamabyaliro
Aline Engo
Bibiche Mvete
Jerry Liwono
Mariano Lusakibanza
Gauthier Mesia
Christian Burri
Samuel Mampunza
Gaston Tona
author_sort Didier Nzolo
title Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo
title_short Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo
title_full Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo
title_fullStr Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo
title_full_unstemmed Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo
title_sort development of a pharmacovigilance system in a resource-limited country: the experience of the democratic republic of congo
publisher SAGE Publishing
series Therapeutic Advances in Drug Safety
issn 2042-0994
publishDate 2019-07-01
description Implementation of pharmacovigilance (PV) systems in resource-limited countries is a real endeavor. Despite country- and continent-specific challenges, the Democratic Republic of the Congo (DRC) has been able to develop one of the most active PV systems in the sub-Saharan Africa. The World Health Organization (WHO) regional Office identified the DRC experience to set up a PV system for antimalarial drugs safety monitoring as a ‘best practice’ that needed to be documented in order to help DRC improve its PV system and to be scaled up in other African countries. In response to the WHO request, a best practices and bottlenecks analysis was conducted in 2015. This analysis was updated in 2018 in the light of the minimum requirements of the WHO to set up a PV system taking into account other guidance for PV systems. The following themes were retained for analysis: (1) creation of the national PV center; (2) implementation of PV in the health system; (3) data collection and analysis; (4) collaboration with public health programs; (5) collaboration with the National Regulatory Authority. Lessons learnt from the DRC experience show that it is possible to implement PV systems in order to promote patients’ safety in resource limited sub-Saharan African countries with no guaranteed funding. The ability of national PV centers to collaborate with Public health stakeholders, including public health authorities at all levels as well as public health programs, and to use existing health information systems are considered the main key to success and may substantially reduce the cost of PV activities.
url https://doi.org/10.1177/2042098619864853
work_keys_str_mv AT didiernzolo developmentofapharmacovigilancesysteminaresourcelimitedcountrytheexperienceofthedemocraticrepublicofcongo
AT andreakuemmerle developmentofapharmacovigilancesysteminaresourcelimitedcountrytheexperienceofthedemocraticrepublicofcongo
AT yveslula developmentofapharmacovigilancesysteminaresourcelimitedcountrytheexperienceofthedemocraticrepublicofcongo
AT nsengintamabyaliro developmentofapharmacovigilancesysteminaresourcelimitedcountrytheexperienceofthedemocraticrepublicofcongo
AT alineengo developmentofapharmacovigilancesysteminaresourcelimitedcountrytheexperienceofthedemocraticrepublicofcongo
AT bibichemvete developmentofapharmacovigilancesysteminaresourcelimitedcountrytheexperienceofthedemocraticrepublicofcongo
AT jerryliwono developmentofapharmacovigilancesysteminaresourcelimitedcountrytheexperienceofthedemocraticrepublicofcongo
AT marianolusakibanza developmentofapharmacovigilancesysteminaresourcelimitedcountrytheexperienceofthedemocraticrepublicofcongo
AT gauthiermesia developmentofapharmacovigilancesysteminaresourcelimitedcountrytheexperienceofthedemocraticrepublicofcongo
AT christianburri developmentofapharmacovigilancesysteminaresourcelimitedcountrytheexperienceofthedemocraticrepublicofcongo
AT samuelmampunza developmentofapharmacovigilancesysteminaresourcelimitedcountrytheexperienceofthedemocraticrepublicofcongo
AT gastontona developmentofapharmacovigilancesysteminaresourcelimitedcountrytheexperienceofthedemocraticrepublicofcongo
_version_ 1724634669208567808